{"format":{"id":"tcr-t","name":"TCR-T cell therapies","blurb":"A T-cell receptor engineered to see a peptide from inside the cell presented on an HLA molecule: the antigen and the HLA restriction together decide who the medicine can treat.","axes":["target","hla"],"axisLabels":["Target","HLA restriction"],"components":[{"key":"target","label":"Target"},{"key":"hla","label":"HLA restriction"},{"key":"cellSource","label":"Cell source"},{"key":"format","label":"Format"}]},"counts":{"approved":1,"development":4,"stopped":0,"unclear":0,"untried":2,"drugs":5,"partial":3,"unresolved":0},"coverage":{"total":5,"full":2,"partial":3,"unresolved":0,"pct":100},"rows":[{"key":"target","id":"ctag1b","name":"CTAG1B","href":"/targets/ctag1b/"},{"key":"target","id":"cldn18-2","name":"Claudin 18.2","href":"/targets/cldn18-2/"},{"key":"target","id":"mage-a4","name":"MAGE-A4","href":"/targets/mage-a4/"},{"key":"target","id":"prame","name":"PRAME","href":"/targets/prame/"}],"cols":[{"key":"hla","id":"hla-a02","name":"HLA-A*02","href":"/targets/hla-a/"},{"key":"hla","id":"not-recorded","name":"HLA restriction not recorded"}],"cells":[{"a":{"key":"target","id":"ctag1b","name":"CTAG1B","href":"/targets/ctag1b/"},"b":{"key":"hla","id":"not-recorded","name":"HLA restriction not recorded"},"state":"development","drugs":[{"id":"tbi-1301","name":"TBI-1301","route":"/drugs/tbi-1301/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{},"evidence":[{"record":"tbi-1301","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tbi-1301/"},{"record":"nct07174427","field":"status","kind":"trial","state":"development","label":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma: phase 3, recruiting","href":"/trials/nct07174427/"},{"record":"registry:tbi-1301","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/tbi-1301/#registry"}],"reasons":[]},{"a":{"key":"target","id":"ctag1b","name":"CTAG1B","href":"/targets/ctag1b/"},"b":{"key":"hla","id":"hla-a02","name":"HLA-A*02","href":"/targets/hla-a/"},"state":"development","drugs":[{"id":"letetresgene-autoleucel","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"cellSource":[{"key":"cellSource","id":"autologous","name":"Autologous"}],"format":[{"key":"format","id":"affinity-enhanced-tcr","name":"Affinity-enhanced TCR","href":"/technologies/tcr-t/"}]},"evidence":[{"record":"letetresgene-autoleucel","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/letetresgene-autoleucel/"},{"record":"registry:letetresgene-autoleucel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/letetresgene-autoleucel/#registry"}],"reasons":[]},{"a":{"key":"target","id":"cldn18-2","name":"Claudin 18.2","href":"/targets/cldn18-2/"},"b":{"key":"hla","id":"not-recorded","name":"HLA restriction not recorded"},"state":"development","drugs":[{"id":"tac01-cldn18-2","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/","state":"development","status":"phase-2"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"cellSource":[{"key":"cellSource","id":"autologous","name":"Autologous"}],"format":[{"key":"format","id":"tac","name":"T-cell antigen coupler","href":"/technologies/tcr-t/"}]},"evidence":[{"record":"tac01-cldn18-2","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tac01-cldn18-2/"},{"record":"nct05862324","field":"status","kind":"trial","state":"development","label":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3): phase 1/2, active","href":"/trials/nct05862324/"},{"record":"registry:tac01-cldn18-2","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/tac01-cldn18-2/#registry"}],"reasons":[]},{"a":{"key":"target","id":"mage-a4","name":"MAGE-A4","href":"/targets/mage-a4/"},"b":{"key":"hla","id":"hla-a02","name":"HLA-A*02","href":"/targets/hla-a/"},"state":"approved","drugs":[{"id":"afamitresgene-autoleucel","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","state":"approved","status":"approved"}],"counts":{"approved":1,"development":0,"stopped":0,"unclear":0},"parts":{"format":[{"key":"format","id":"affinity-enhanced-tcr","name":"Affinity-enhanced TCR","href":"/technologies/tcr-t/"}]},"evidence":[{"record":"afamitresgene-autoleucel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/afamitresgene-autoleucel/"},{"record":"afamitresgene-autoleucel","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Advanced MAGE-A4+ synovial sarcoma, HLA-A*02+ (age ≥12 from 2026)","href":"/drugs/afamitresgene-autoleucel/"},{"record":"afamitresgene-autoleucel","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"nct04044768","field":"status","kind":"trial","state":"development","label":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma: phase 2, active","href":"/trials/nct04044768/"},{"record":"nct05642455","field":"status","kind":"trial","state":"development","label":"SPEARHEAD-3 Pediatric Study: phase 1/2, recruiting","href":"/trials/nct05642455/"},{"record":"registry:afamitresgene-autoleucel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/afamitresgene-autoleucel/#registry"}],"reasons":[]},{"a":{"key":"target","id":"prame","name":"PRAME","href":"/targets/prame/"},"b":{"key":"hla","id":"not-recorded","name":"HLA restriction not recorded"},"state":"development","drugs":[{"id":"ima203","name":"IMA203","route":"/drugs/ima203/","state":"development","status":"phase-3"}],"counts":{"approved":0,"development":1,"stopped":0,"unclear":0},"parts":{"cellSource":[{"key":"cellSource","id":"autologous","name":"Autologous"}]},"evidence":[{"record":"ima203","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ima203/"},{"record":"nct06743126","field":"status","kind":"trial","state":"development","label":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma: phase 3, recruiting","href":"/trials/nct06743126/"},{"record":"registry:ima203","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/ima203/#registry"}],"reasons":[]}],"components":{"target":[{"key":"target","id":"ctag1b","name":"CTAG1B","href":"/targets/ctag1b/","count":2,"drugIds":["letetresgene-autoleucel","tbi-1301"],"states":{"approved":0,"development":2,"stopped":0,"unclear":0}},{"key":"target","id":"cldn18-2","name":"Claudin 18.2","href":"/targets/cldn18-2/","count":1,"drugIds":["tac01-cldn18-2"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}},{"key":"target","id":"mage-a4","name":"MAGE-A4","href":"/targets/mage-a4/","count":1,"drugIds":["afamitresgene-autoleucel"],"states":{"approved":1,"development":0,"stopped":0,"unclear":0}},{"key":"target","id":"prame","name":"PRAME","href":"/targets/prame/","count":1,"drugIds":["ima203"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}}],"hla":[{"key":"hla","id":"hla-a02","name":"HLA-A*02","href":"/targets/hla-a/","count":2,"drugIds":["afamitresgene-autoleucel","letetresgene-autoleucel"],"states":{"approved":1,"development":1,"stopped":0,"unclear":0}}],"cellSource":[{"key":"cellSource","id":"autologous","name":"Autologous","count":3,"drugIds":["ima203","letetresgene-autoleucel","tac01-cldn18-2"],"states":{"approved":0,"development":3,"stopped":0,"unclear":0}}],"format":[{"key":"format","id":"affinity-enhanced-tcr","name":"Affinity-enhanced TCR","href":"/technologies/tcr-t/","count":2,"drugIds":["afamitresgene-autoleucel","letetresgene-autoleucel"],"states":{"approved":1,"development":1,"stopped":0,"unclear":0}},{"key":"format","id":"tac","name":"T-cell antigen coupler","href":"/technologies/tcr-t/","count":1,"drugIds":["tac01-cldn18-2"],"states":{"approved":0,"development":1,"stopped":0,"unclear":0}}]},"drugs":[{"id":"afamitresgene-autoleucel","name":"Afamitresgene autoleucel","route":"/drugs/afamitresgene-autoleucel/","status":"approved","modality":"TCR-T (MAGE-A4)","state":"approved","confidence":"high","fields":["targets","mechanism","modality"],"components":{"target":{"id":"mage-a4","name":"MAGE-A4","href":"/targets/mage-a4/","confidence":"high","from":["targets"],"detail":null},"hla":{"id":"hla-a02","name":"HLA-A*02","href":"/targets/hla-a/","confidence":"high","from":["targets"],"detail":null},"format":{"id":"affinity-enhanced-tcr","name":"Affinity-enhanced TCR","href":"/technologies/tcr-t/","confidence":"high","from":["mechanism","modality"],"detail":null}},"evidence":[{"record":"afamitresgene-autoleucel","field":"status","kind":"drug","state":"approved","label":"Drug record status: approved","href":"/drugs/afamitresgene-autoleucel/"},{"record":"afamitresgene-autoleucel","field":"approvals[0]","kind":"approval","state":"approved","label":"US 2024: Advanced MAGE-A4+ synovial sarcoma, HLA-A*02+ (age ≥12 from 2026)","href":"/drugs/afamitresgene-autoleucel/"},{"record":"afamitresgene-autoleucel","field":"regional.US","kind":"regional","state":"approved","label":"FDA (US): approved 2024","href":"/regulatory/regions/"},{"record":"nct04044768","field":"status","kind":"trial","state":"development","label":"Spearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell Liposarcoma: phase 2, active","href":"/trials/nct04044768/"},{"record":"nct05642455","field":"status","kind":"trial","state":"development","label":"SPEARHEAD-3 Pediatric Study: phase 1/2, recruiting","href":"/trials/nct05642455/"},{"record":"registry:afamitresgene-autoleucel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/afamitresgene-autoleucel/#registry"}],"reasons":[]},{"id":"ima203","name":"IMA203","route":"/drugs/ima203/","status":"phase-3","modality":"TCR-T cell therapy","state":"development","confidence":"high","fields":["targets","mechanism"],"components":{"target":{"id":"prame","name":"PRAME","href":"/targets/prame/","confidence":"high","from":["targets"],"detail":null},"cellSource":{"id":"autologous","name":"Autologous","href":null,"confidence":"high","from":["mechanism"],"detail":null}},"evidence":[{"record":"ima203","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/ima203/"},{"record":"nct06743126","field":"status","kind":"trial","state":"development","label":"SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma: phase 3, recruiting","href":"/trials/nct06743126/"},{"record":"registry:ima203","kind":"registry","state":"development","label":"ClinicalTrials.gov: 2 recruiting, active or planned studies (fetched 2026-09-21)","href":"/drugs/ima203/#registry"}],"reasons":[]},{"id":"letetresgene-autoleucel","name":"Letetresgene autoleucel","route":"/drugs/letetresgene-autoleucel/","status":"phase-2","modality":"TCR-T (NY-ESO-1)","state":"development","confidence":"high","fields":["target record (drugs field)","targets","mechanism","modality"],"components":{"target":{"id":"ctag1b","name":"CTAG1B","href":"/targets/ctag1b/","confidence":"high","from":["target record (drugs field)"],"detail":null},"hla":{"id":"hla-a02","name":"HLA-A*02","href":"/targets/hla-a/","confidence":"high","from":["targets"],"detail":null},"cellSource":{"id":"autologous","name":"Autologous","href":null,"confidence":"high","from":["mechanism"],"detail":null},"format":{"id":"affinity-enhanced-tcr","name":"Affinity-enhanced TCR","href":"/technologies/tcr-t/","confidence":"high","from":["mechanism","modality"],"detail":null}},"evidence":[{"record":"letetresgene-autoleucel","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/letetresgene-autoleucel/"},{"record":"registry:letetresgene-autoleucel","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/letetresgene-autoleucel/#registry"}],"reasons":[]},{"id":"tac01-cldn18-2","name":"TAC01-CLDN18.2","route":"/drugs/tac01-cldn18-2/","status":"phase-2","modality":"TCR-T cell therapy","state":"development","confidence":"high","fields":["targets","mechanism","modality"],"components":{"target":{"id":"cldn18-2","name":"Claudin 18.2","href":"/targets/cldn18-2/","confidence":"high","from":["targets"],"detail":null},"cellSource":{"id":"autologous","name":"Autologous","href":null,"confidence":"high","from":["mechanism"],"detail":null},"format":{"id":"tac","name":"T-cell antigen coupler","href":"/technologies/tcr-t/","confidence":"high","from":["mechanism","modality"],"detail":null}},"evidence":[{"record":"tac01-cldn18-2","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 2","href":"/drugs/tac01-cldn18-2/"},{"record":"nct05862324","field":"status","kind":"trial","state":"development","label":"TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3): phase 1/2, active","href":"/trials/nct05862324/"},{"record":"registry:tac01-cldn18-2","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/tac01-cldn18-2/#registry"}],"reasons":[]},{"id":"tbi-1301","name":"TBI-1301","route":"/drugs/tbi-1301/","status":"phase-3","modality":"TCR-T cell therapy (per the sponsor's pipeline page; form not stated in the registry record)","state":"development","confidence":"medium","fields":["summary"],"components":{"target":{"id":"ctag1b","name":"CTAG1B","href":"/targets/ctag1b/","confidence":"medium","from":["summary"],"detail":null}},"evidence":[{"record":"tbi-1301","field":"status","kind":"drug","state":"development","label":"Drug record status: phase 3","href":"/drugs/tbi-1301/"},{"record":"nct07174427","field":"status","kind":"trial","state":"development","label":"Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma: phase 3, recruiting","href":"/trials/nct07174427/"},{"record":"registry:tbi-1301","kind":"registry","state":"development","label":"ClinicalTrials.gov: 1 recruiting, active or planned study (fetched 2026-09-21)","href":"/drugs/tbi-1301/#registry"}],"reasons":[]}],"unresolved":[],"stopped":[],"proposed":[],"note":"Every state is derived from the records named in evidence; untried means no medicine in this corpus combines the two parts. Proposed cells are hypotheses from the open pipeline (docs/OPEN-PIPELINE.md), not records of a medicine. CC BY-NC 4.0, attribute Data from OnCo (onco.cc). Not medical advice."}